Notice Board

In this issue we feature:

–  Diagnosing and managing MI-VSD
–  ESC QIs: Care and outcomes of adults with HF
–  Clinical impact of CMR for CHD
–  Palliative pharmacotherapy for CVD
–  Periprocedural management and multidisciplinary care pathways: CIEDs
–  Hereditary transthyretin amyloidosis
–  Chronic heart failure
–  Transthyretin amyloid cardiomyopathy
–  Hypercholesterolaemia
–  Half of Australians unaware of major CVD risk factor
–  Schizophrenia: Cardiovascular risk assessment and management
–  Team-based care to overcome therapeutic inertia in PAD
–  COVID-19 resources
–  Conferences, workshops and CPD

Download issue here (pdf)

In this issue: 

• Temporal trends in lifetime risk of AF and its complications 
• Semaglutide in patients with obesity-related heart failure and type 2 diabetes 
• Cardiac sarcoidosis in middle-aged adults with high-grade atrioventricular block 
• Use of deep learning to estimate cardiovascular risk from chest radiographs 
• 12 months of ticagrelor ± aspirin after PCI 
• Bleeding risk in patients with AF using diltiazem with apixaban or rivaroxaban 
• Direct oral anticoagulants for stroke prevention in patients with device-detected AF 
• Long COVID and cardiovascular disease 
• Invasive vs conservative management of older patients with NSTEMI 
• Patterns of AF recurrence after catheter ablation 

Download Cardiology_Research_Review_Issue_113

In this edition:

–  Apolipoprotein A1 infusions after acute MI
–  TAVI in patients with high-risk native aortic regurgitation
–  Combined use of GLP-1 agonists + SGLT2 inhibitors in patients with T2D
–  Cardiovascular effects of oral ketone ester treatment in patients with HFrEF
–  Impact of optimal vs poor statin adherence after STEMI
–  Transcatheter vs surgical treatment of aortic valve stenosis
–  Empagliflozin after acute MI
–  Use of artificial intelligence to predict AF
–  Aspirin vs clopidogrel for long-term maintenance after coronary stenting
–  Is excess apolipoprotein B associated with cardiovascular risk?

Download the Cardiology Research Review: Issue 165, with commentary by A/Prof John Amerena

In this issue:

• CSANZ Position Statement on using TTE
• Standardising paediatric echocardiography reporting
• CPG: Managing arterial hypertension
• Aortic stenosis: Update in monitoring and management
• Cardiac murmurs in children
• Changes to the prescription process
• Expansion of the CTG PBS Co-Payment Program
• PBS updates in June 2024
• PBS updates in July 2024
• Innovative business model to deliver cardiac rehabilitation
• RACP Member Wellbeing Framework available
• Radiation exposure in interventional echocardiography
• COVID-19 resources
• Conferences, workshops and CPD

Download the Cardiology Practice Review Issue 36, with commentary by Dr Janette Tenne

In this issue:

–  2024 Australia–New Zealand Expert Consensus Statement on CA
–  Managing elevated BP in the acute care setting
–  Pre- and post-procedural cardiac imaging in electrophysiology
–  Chronic HF in children and adolescents with CHD
–  Managing hypertrophic cardiomyopathy
–  Managing lower extremity PAD
–  Regulatory news
–  Australian experience with R-PCI
–  Implementing obesity science into clinical practice
–  Performance and quality measures for spontaneous ICH
–  COVID-19 resources
–  Conferences, workshops and CPD

Download the Australian Cardiology Practice Review: Issue 35, with commentary by Dr Jannette Tenne (pdf)

In this issue:

–  Guideline for the management of hypertrophic cardiomyopathy
–  Performance and quality measures for valvular and structural heart disease
–  Expert Consensus Statement on cardiac amyloidosis
–  Effect of SGLT2 inhibitors on heart failure outcomes
–  Semaglutide reduces the need for loop diuretics in heart failure
–  Vaccination against COVID-19 and clinical outcomes in heart failure
–  SEQUOIA-HCM trial in obstructive hypertrophic cardiomyopathy
–  Nurse Practitioner prescribing for empagliflozin amended
–  Lokelma approved for hyperkalaemia
–  Artificial intelligence and its role in diagnosing heart failure
–  Yoga linked to improved heart failure symptoms
–  Robot-assisted PCI

Download Australian Heart Failure Practice Review: Issue 5, with commentary by Prof Andrew Coats. 

In this edition:

–  Dapagliflozin in acute HF
–  ARNI vs. placebo in congenital systemic right ventricular HF
–  Contemporary use and implications of β-blockers in HFMREF/HFPEF
–  Managing iron deficiency in Asian HF patients
–  β-blocker withdrawal and functional capacity improvement in HFPEF
–  Phenotyping HF by genetics and associated conditions
–  Impact of visit volume on effectiveness of electronic tools to improve HF care
–  Pharmacological treatments in HFMREF/HFPEF
–  Dementia risk with statins in HF
–  Impact of rapid up-titration of GDMT on QOL in acute HF

Download the Heart Failure Research Review: Issue 86, with commentary by Dr Mark Nolan 

In this edition:

–  A culturally informed model of care for Indigenous patients with ACS
–  Lipoprotein(a) levels and cardiovascular risk reduction with icosapent ethyl
–  Exercise therapy for chronic symptomatic peripheral artery disease
–  Uniform or sex-specific cardiac troponin thresholds to rule out MI?
–  Extended clopidogrel monotherapy vs DAPT in high-risk patients with ACS
–  Beta-blocker use post-MI in patients with preserved ejection fraction
–  Antihypertensive drug therapy and risk of dementia in the elderly
–  Effects of statin therapy on new-onset diabetes and worsening glycaemia
–  Efficacy and safety of dapagliflozin in patients with acute HF
–  Preventive PCI for vulnerable atherosclerotic coronary plaques

Download the Cardiology Research Review, Issue 164, with commentary by A/Prof John Amerena.(pdf)

Download the Research Review Education Series: Secondary events in CVD – Triglycerides as a marker of residual risk, with commentary by A/Prof John Amerena (pdf)